Olivier Martinon is Vice President, External Innovation at Zoetis where he leads the team responsible for identifying and developing strategic partnerships that enhance the company’s own research and development pipeline. He joined Zoetis via its legacy companies in 2006, and has previously held roles at the company including Executive Research Director for Zoetis’ global therapeutics group and led portfolio projects and mentored researchers critical to securing global approvals for our new monoclonal antibodies (mAbs) to control pain associated with osteoarthritis in dogs and cats. He also previously led the livestock therapeutic area identifying key external partners to advance that portfolio, was the original champion in creating the biotherapeutic discipline within Zoetis’ Veterinary Medicine Research & Development organization. Dr. Martinon completed his veterinary studies in Paris-Alfort France in 1990, and he studied molecular biology at CIRAD before moving to a DEA/MS in Biotechnology from Paris VI. He then pursued a cursus in Immunology for three years with Institut Pasteur Professor. Olivier is French and American having grown up in Lyon (France) and moved to the U.S. in 2002. He and his wife live near Grand Rapids, Michigan and have three grown sons.